Minimal residual disease in acute myeloid leukaemia.

ABSTRACT: Technological advances in the laboratory have led to substantial improvements in clinical decision making through the introduction of pretreatment prognostic risk stratification factors in acute myeloid leukaemia (AML). Unfortunately, similar progress has not been made in treatment response criteria, with the definition of 'complete remission' in AML largely unchanged for over half a century. Several clinical trials have demonstrated that high-sensitivity measurements of residual disease burden during or after treatment can be performed, that results are predictive for clinical outcome and can be used to improve outcomes by guiding additional therapeutic intervention to patients in clinical complete remission, but at increased relapse risk. We review these recent trials, the characteristic

SUBMITTER: Hourigan CS 

PROVIDER: S-EPMC4163748 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature